For HCPsIntended for HCPs.
All Authors
SK

Infectious Diseases

Dr. Simran Kohli

Recent Articles

8 total

Infectious Disease

FDA Authorizes Nirmatrelvir-Ritonavir (Paxlovid) for COVID-19: 89% Hospitalization Reduction in EPIC-HR Trial

FDA authorizes nirmatrelvir-ritonavir (Paxlovid) for COVID-19: 89% hospitalization reduction in high-risk adults.

Apr 29, 2026|3 min read|NEJM

infectious disease

Long COVID Management Update 2025: New Insights for Primary Care Providers

2025 long COVID management update: key insights for primary care providers on addressing persistent symptoms and improving patient outcomes.

Apr 27, 2026|3 min read|NEJM

Infectious Disease

WHO's 2026 Guidelines: A Comprehensive Approach to Combatting Antimicrobial Resistance

Explore WHO's 2026 guidelines on antimicrobial resistance, focusing on surveillance, infection control, and research investment.

Apr 24, 2026|2 min read|The Lancet

Medical Research

Improve Ovarian Cancer Detection with Personalized Risk Score

Enhance patient outcomes with a cost-effective tool that combines blood test results and age for accurate ovarian cancer detection in women over 50.

Apr 20, 2026|3 min read|Medical Xpress

Digital Health

Automate 90% of Intake Workflows with AI

Discover how AI-powered automation can streamline post-acute care workflows, freeing staff to focus on patient care and reducing administrative burdens.

Apr 14, 2026|2 min read|HIT Consultant

Medical Research

Plant-Based Diet Cuts Type 2 Diabetes Risk

Discover how a plant-based diet can lower type 2 diabetes risk while reducing greenhouse gas emissions, benefiting both human and planetary health.

Apr 8, 2026|3 min read|Medical Xpress

Digital Health

Stay Ahead with Daily Digital Health Updates

Get the latest digital health news, trends, and insights to enhance patient care and stay informed about industry developments and innovations.

Apr 5, 2026|4 min read|Digital Health News

Medical Research

Reuse Patient Studies to Cut Drug Dev Costs

Discover how reusing existing patient preference studies can optimize resource allocation and streamline drug development processes, reducing costs and improving efficiency.

Mar 24, 2026|2 min read|Medical Xpress